Xencor, Inc.
↗Pasadena, California, USA
Xencor is a publicly traded clinical-stage biopharmaceutical company founded in 1997 that specializes in the discovery and development of engineered monoclonal antibodies and bispecific antibodies for the treatment of cancer, autoimmune diseases, and inflammatory conditions. The company is built on superior Fc domain expertise and is an industry leader in bispecific antibody development. Xencor uses its proprietary XmAb® protein engineering platform to develop antibody therapeutics with improved potency, half-life, and stability. The platform has enabled the development of more than 20 clinical programs and three marketed medicines through partnerships with major pharmaceutical companies.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Biopharmaceutical - Monoclonal & Bispecific Antibodies
SIZE & FINANCIALS
Employees:201-500
Revenue:$125M-$150M
Founded:1997
Ownership:public
Status:operating
FUNDING
Stage:Public (IPO Dec 2013)
Total Raised:$160.2M (pre-IPO)
Investors:MedImmune Ventures, Novo Nordisk, HealthCare Ventures, Foresite Capital, Amgen Business Development, Oxford Bioscience Partners, Johnson & Johnson Innovation
STOCK
Exchange:NASDAQ
Ticker:XNCR
Market Cap:$1.07B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1
Modalities:Monoclonal Antibodies, Bispecific Antibodies, Fc-optimized antibodies, T-cell engaging bispecifics, Cytokine therapeutics
Active Trials:8
Trial Phases:Phase 1: 5 | Phase 2: 2
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Amgen (Cancer immunotherapy & inflammation collaboration, $45M upfront, up to $1.7B milestones), MorphoSys (Tafasitamab/Monjuvi - licensed 2010, now with Incyte), Novartis, Merck, CSL/Janssen, Alexion (now AstraZeneca), Boehringer Ingelheim, Novo Nordisk, MD Anderson Cancer Center (collaboration on XmAb candidates)
COMPETITION
Position:Leader
Competitors:Genmab, Amgen (partly competitor, partly partner), Regeneron, Arcus Biosciences, Forty Seven Inc, Surface Oncology, Jounce Therapeutics
LEADERSHIP
Key Executives:
Bassil I. Dahiyat, Ph.D. - President & CEO
John R. Desjarlais, Ph.D. - EVP, Research & Chief Scientific Officer
Nancy Valente, M.D. - EVP & Chief Development Officer
Allen S. Yang, M.D. - Senior VP/Chief Medical Officer
Scientific Founders:Bassil I. Dahiyat, Ph.D., Stephen Mayo, Ph.D. (Caltech)
Board Members:Bassil I. Dahiyat (Chairman & CEO), Ellen G. Feigal, M.D., Todd Simpson (joined March 2025), Raymond Deshaies, Ph.D. (joined July 2025)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Xencor, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Xencor, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.